Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

ICER provides vote of confidence to AbbVie’s Rinvoq as it makes substantial leap in cost-effectiveness, says GlobalData

Following the news that ICER has published its latest draft of the evidence report, ‘Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value’; Rose Joachim, Pharmaceutical Analyst at GlobalData, a leading data and analytics company, offers her view: “Following the surprise withdrawal of ICER’s initial draft evidence report last month, the organization’s latest draft, published […]
Read more

North America leads in number of strategic pharma partnerships between 2014 and H1 2019

From 2014 to the first half (H1) of 2019, there were more than 1,300 separate strategic partnerships and 1,000 licensing agreements made in the global pharmaceutical industry that involved gene therapy, immuno-oncology, microbiome and orphan drug therapeutics, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Deal-Making Trends in Pharma – […]
Read more

Deal activity remains vibrant within the pharmaceutical industry between 2014 and H1 2019

From 2014 to the first half (H1) of 2019, the pharmaceutical and healthcare industry recorded 2,882 deals that fell within the gene therapy, immuno-oncology, microbiome and orphan drug space. Comprising strategic partnerships, licensing agreements and mergers and acquisitions (M&As), these deals were worth $1,068.8bn in total, according to GlobalData, a leading data and analytics company. […]
Read more

M&A activity within the pharmaceutical industry remains high in H1 2019

From 2014 to the first half (H1) of 2019, the global pharmaceutical industry saw more than 400 mergers and acquisitions (M&A) in the gene therapy, immuno-oncology, microbiome and orphan drugs therapeutic categories. The M&As that involved immuno-oncology and/or orphan drug assets continue to dominate this deal space, according to GlobalData, a leading data and analytics […]
Read more

Concerted efforts required by both Indian pharma industry and government to boost innovation in India, says GlobalData

The Indian Pharmaceutical Alliance (IPA) has recently urged the government to set up a fund to boost technological innovation in the bio/pharma space. This push to promote innovation by creating a research ecosystem is important because the Indian pharmaceutical industry is set to grow from nearly US$31bn in 2018 to more than US$38.0bn by 2022, says GlobalData, […]
Read more

Global hidradenitis suppurativa market set to reach $1.81bn by 2028

The hidradenitis suppurativa (HS) market is expected to grow from $898m in 2018 to $1.81bn in 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 7.2%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028’, states that […]
Read more

First-in-human, Phase I clinical trial holds great promise for the development of an effective vaccine against genital chlamydia

Recently, a first-in-human, Phase I clinical trial was successfully completed for a novel chlamydia vaccine. The trial results hold great promise for the development of an effective vaccine against genital chlamydia, says GlobalData, a leading data and analytics company. The trial aimed to evaluate both the safety and efficiency of the vaccine, with the latter […]
Read more

Healthcare professionals say the UK WILL NOT leave the EU on the current withdrawal agreement on 31 October in latest GlobalData survey

Healthcare industry professionals around the world believe that Brexit will not happen on the current withdrawal agreement on 31 October, but there will also be no cancellation of Brexit, the latest survey data from GlobalData, a leading data and analytics company, suggests. GlobalData’s latest report, ‘Brexit and the Healthcare Industry – Implications for Pharma, Q2 […]
Read more

Manipulated Zolgensma data may add to further woes for Novartis

Zolgensma’s recent challenge of finding favor with the majority of the insurance companies in the US may just be about to get tougher with the news on manipulation in pre-clinical data. Vinie Varkey, Senior Analyst of Neurology & Ophthalmology at GlobalData, a leading data and analytics company, offers her view on what this means for […]
Read more

Precision medicine set to make steady headway in Japan, says GlobalData

Japan has recently become the first country to approve Roche/Chugai’s personalized medicine Rozlytrek (entrectinib) for adult and pediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive advanced recurrent solid tumors. Against this back drop, precision medicine is set to make steady headway in Japan, says GlobalData, a leading data and analytics company. Sasmitha Sahu, Pharma […]
Read more

Despite resubmission of Viaskin Peanut BLA, AR-101’s likely first-to-market advantage could still setback DBV Technologies

Following the news that DBV Technologies has submitted a biologics license application (BLA) to the US FDA for Viaskin Peanut, an epicutaneous immunotherapy for the treatment of peanut allergy, Rose Joachim, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Although DBV’s recent BLA resubmission for Viaskin Peanut has […]
Read more

Almost 70% of CMO high-containment facilities in Europe can be found in the 5EU and Switzerland

Approximately 69% of contract manufacturing organization (CMO) high-containment facilities in Europe can be found in the five major European markets (5EU*) and Switzerland, according to GlobalData, a leading data and analytics company. GlobalData’s latest research reveals that the European contract manufacturing industry has invested heavily in containment capabilities. Adam Bradbury, PharmSource Analyst at GlobalData, comments: […]
Read more

South Korea’s pharma-biotech space to attract foreign investment as market set to be worth US$23.2bn by 2022, says GlobalData

South Korea’s plans to invest more than US$1.7bn in its biotechnology and biopharmaceutical sectors over the next five years will attract foreign investment as pharmaceutical market growth is set to increase from nearly US$19.5bn in 2018 to more than US$23.2bn by 2022, says GlobalData, a leading data and analytics company. Prashant Khadayate, Pharma Analyst at […]
Read more

Lupus pipeline sees high levels of innovation with 43% first-in-class, says GlobalData

The systemic lupus erythematosus (SLE) pipeline is characterized by a high level of first-in-class innovation when compared to other therapy areas and the industry as a whole, says GlobalData, a leading data and analytics company.  GlobalData’s recent report, ‘Systemic Lupus Erythematosus: Programs Targeting Cytokine and Growth Factor Signaling Dominate First-in-Class Pipeline’, reveals that the high […]
Read more

Bayer and Orion’s Nubeqa could gain regulatory approval in EU and Japan next year despite being late-to-market for prostate cancer

Following the news that Bayer and Orion’s Nubeqa (darolutamide) has gained US Food and Drug Administration (FDA) approval for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) in only five months, Heather Leach, PhD, Healthcare Director at GlobalData, a leading data and analytics company, offers her view on the impact of Nubeqa on the prostate […]
Read more
1 … 103 104 105 106 107 108